Processes for intermediates for macrocyclic compounds
AssigneeTranzyme Pharma Inc.
InventorsÉric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.
Claims15
A compound having the following structure:
- wherein:
- W is selected from the group consisting of —NHPG and —NH2,
- X is —OH or —OPG;
- and
- PG is a protecting group.
A compound having the following structure:
- wherein:
- W is —OPG,
- X is —OH or —OPG;
- and
- PG is a protecting group.
Dependencies are inferred from the claim text.